World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Biology and Biochemistry 57 13769 12667 5826 5217 380 12520

Virginia F. Borges publications per year

The chart shows the history of publications by Virginia F. Borges between 2001 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Virginia F. Borges published across 25 years, from 2001 to 2025, averaging 20.5 papers a year. Output peaked at 121 publications in 2023. 87 of the 513 publications appeared in the last two years.

No. of publications
25 50 75 100
Bar chart. Horizontal axis: year, 2001 to 2025. Vertical axis: number of publications, 0 to 121. Peak 121 publications in 2023. 2001: 2 publications 2002: 1 publication 2003: 2 publications 2004: 1 publication 2005: 3 publications 2006: 3 publications 2007: 3 publications 2008: 4 publications 2009: 12 publications 2010: 8 publications 2011: 10 publications 2012: 8 publications 2013: 22 publications 2014: 19 publications 2015: 21 publications 2016: 16 publications 2017: 19 publications 2018: 19 publications 2019: 24 publications 2020: 39 publications 2021: 42 publications 2022: 27 publications 2023: 121 publications 2024: 47 publications 2025: 40 publications
2001 2025

513 publications in total across all disciplines

View publications per year as a table
Virginia F. Borges: publications per year, 2001 to 2025
Year Publications
2001 2
2002 1
2003 2
2004 1
2005 3
2006 3
2007 3
2008 4
2009 12
2010 8
2011 10
2012 8
2013 22
2014 19
2015 21
2016 16
2017 19
2018 19
2019 24
2020 39
2021 42
2022 27
2023 121
2024 47
2025 40
Total 513
Download as CSV

Virginia F. Borges publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Virginia F. Borges sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 100 bars. Horizontal axis: publications, 47–56 to 1,028+. Vertical axis: number of scientists, 0 to 980. Most scientists, 980, have 127–136 publications. The last bar groups every scientist with 1,028 publications or more. The highlighted bar, 377–386 publications, is where this scientist sits. 47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 413 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 848 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 949 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 840 scientists 207–216 publications: 733 scientists 217–226 publications: 708 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 417 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 196 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 59 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientist 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientist 1,028+ publications: 100 scientists
47–56 publications 1,028+

This scientist: 380 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

View publications distribution as a table
Number of Biology and Biochemistry scientists by publication count, Research.com 2026 ranking edition. Based on 19,587 ranked scientists.
Publications Scientists This scientist
47–56 8
57–66 35
67–76 106
77–86 231
87–96 413
97–106 546
107–116 704
117–126 848
127–136 980
137–146 942
147–156 969
157–166 949
167–176 951
177–186 915
187–196 787
197–206 840
207–216 733
217–226 708
227–236 651
237–246 605
247–256 510
257–266 524
267–276 434
277–286 417
287–296 350
297–306 363
307–316 315
317–326 296
327–336 261
337–346 240
347–356 219
357–366 196
367–376 154
377–386 161 380
387–396 155
397–406 145
407–416 124
417–426 112
427–436 132
437–446 116
447–456 99
457–466 81
467–476 91
477–486 80
487–496 80
497–506 59
507–516 36
517–526 46
527–536 54
537–546 44
547–556 43
557–566 43
567–576 42
577–586 25
587–596 34
597–606 23
607–616 33
617–626 31
627–636 27
637–646 25
647–656 28
657–666 34
667–676 18
677–686 16
687–696 10
697–706 12
707–716 21
717–726 12
727–736 12
737–746 10
747–756 7
757–766 13
767–776 15
777–786 13
787–796 9
797–806 9
807–816 7
817–826 4
827–836 9
837–846 7
847–856 3
857–866 5
867–876 5
877–886 11
887–896 3
897–906 4
907–916 7
917–926 5
927–936 6
937–946 6
947–956 3
957–966 7
967–976 2
977–986 2
987–996 1
997–1,006 5
1,007–1,016 2
1,017–1,026 2
1,027 1
1,028+ 100
Download as CSV

Virginia F. Borges D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Virginia F. Borges sits on this spectrum.

No. of scientists
250 500 750 1,000 1,250
Bar chart with 65 bars. Horizontal axis: D-Index, 40–41 to 167+. Vertical axis: number of scientists, 0 to 1,253. Most scientists, 1,253, have 58–59 D-Index. The last bar groups every scientist with 167 D-Index or more. The highlighted bar, 56–57 D-Index, is where this scientist sits. 40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 316 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 899 scientists 52–53 D-Index: 1,025 scientists 54–55 D-Index: 1,149 scientists 56–57 D-Index: 1,235 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,162 scientists 62–63 D-Index: 1,130 scientists 64–65 D-Index: 1,031 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 714 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 71 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40–41 D-Index 167+

This scientist: 57 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

View D-Index distribution as a table
Number of Biology and Biochemistry scientists by D-index, Research.com 2026 ranking edition. Based on 19,587 ranked scientists.
D-Index Scientists This scientist
40–41 80
42–43 183
44–45 316
46–47 504
48–49 718
50–51 899
52–53 1,025
54–55 1,149
56–57 1,235 57
58–59 1,253
60–61 1,162
62–63 1,130
64–65 1,031
66–67 897
68–69 814
70–71 714
72–73 709
74–75 596
76–77 512
78–79 473
80–81 412
82–83 373
84–85 358
86–87 285
88–89 273
90–91 227
92–93 208
94–95 193
96–97 153
98–99 157
100–101 148
102–103 120
104–105 113
106–107 100
108–109 86
110–111 67
112–113 71
114–115 73
116–117 64
118–119 53
120–121 60
122–123 54
124–125 43
126–127 38
128–129 49
130–131 26
132–133 18
134–135 23
136–137 32
138–139 32
140–141 27
142–143 19
144–145 22
146–147 12
148–149 16
150–151 14
152–153 10
154–155 13
156–157 10
158–159 7
160–161 9
162–163 13
164–165 4
166 4
167+ 98
Download as CSV

Overview

Virginia F. Borges is affiliated with the University of Colorado Boulder in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong focus on oncology-related studies.

The scientist's main subfields of study include Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics, and Public Health, Environmental and Occupational Health. Their research covers major topics such as Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Cancer Risks and Factors, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Reproductive Biology and Fertility, and BRCA gene mutations in cancer.

Recent publications reflect Virginia F. Borges's focus on breast cancer and cancer therapies. Notable papers include:

  • Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial (2020, Journal of Clinical Oncology)
  • Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis (2021, Annals of Oncology)
  • Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer (2023, New England Journal of Medicine)
  • NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (2022, Journal of Clinical Oncology)
  • Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases (2022, JAMA Oncology)

Frequent co-authors in Virginia F. Borges's work include:

  • Ann H. Partridge
  • Kathryn J. Ruddy
  • Steven E. Come
  • Lidia Schapira
  • Shoshana M. Rosenberg

The scientist regularly publishes in several key venues, notably:

  • Cancer Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Annals of Oncology
  • npj Breast Cancer

This overview presents Virginia F. Borges as a researcher contributing extensively to breast cancer therapy and related oncological studies, with a significant body of work addressing clinical outcomes, treatment modalities, and cancer biology within a multidisciplinary context.

Best Publications

  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

    Rashmi K Murthy;Sherene Loi;Alicia Okines;Elisavet Paplomata

  • Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.

    David Avigan;Baldev Vasir;Jianlin Gong;Virginia Borges

  • Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2

    Traci R. Lyons;Jenean O'Brien;Virginia F. Borges;Virginia F. Borges;Matthew W. Conklin

  • Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study

    Harold J. Burstein;Lyndsay N. Harris;Rebecca Gelman;Susan C. Lester

  • Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer

    Kathryn J. Ruddy;Shari I. Gelber;Rulla M. Tamimi;Elizabeth S. Ginsburg

  • Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial

    Nancy U. Lin;Virginia Borges;Carey Anders;Rashmi K. Murthy

  • NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

    Louis Fehrenbacher;Reena S. Cecchini;Charles E. Geyer;Priya Rastogi

  • Alternatively Activated Macrophages and Collagen Remodeling Characterize the Postpartum Involuting Mammary Gland across Species

    Jenean O'Brien;Traci Lyons;Jenifer Monks;M. Scott Lucia;M. Scott Lucia

  • Pregnancy and Breast Cancer: when They Collide

    Traci R. Lyons;Pepper J. Schedin;Virginia F. Borges

  • Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

    Peter F. Coccia;Alberto S. Pappo;Lynda Beaupin;Virginia F. Borges

  • Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer.

    Eryn B. Callihan;Dexiang Gao;Sonali Jindal;Traci R. Lyons

  • Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium.

    Julie R. Palmer;Emma Viscidi;Melissa A. Troester;Melissa A. Troester;Chi Chen Hong

  • Microenvironment of the involuting mammary gland mediates mammary cancer progression.

    Pepper Schedin;Jenean O’Brien;Michael Rudolph;Torsten Stein

  • Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.

    Richard P. Tobin;Kimberly R. Jordan;William A. Robinson;William A. Robinson;Dana Davis

  • Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study

    Rashmi Murthy;Virginia F Borges;Alison Conlin;Jorge Chaves

  • Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression.

    Holly A. Martinson;Sonali Jindal;Clarissa Durand-Rougely;Virginia F. Borges

  • Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients

    Kimberly R. Jordan;Rodabe N. Amaria;Oscar Ramirez;Eryn B. Callihan

  • Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC).

    Stacy L. Moulder;Virginia F. Borges;Tara Baetz;Tessa Mcspadden

  • Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer.

    Traci R. Lyons;Virginia F. Borges;Virginia F. Borges;Courtney B. Betts;Qiuchen Guo

  • BRCA1 and BRCA2 mutation testing in young women with breast cancer

    Shoshana M. Rosenberg;Kathryn J. Ruddy;Rulla M. Tamimi;Shari Gelber

Frequent Co-Authors

Pepper Schedin
Pepper Schedin Oregon Health & Science University
Ann H. Partridge
Ann H. Partridge Harvard University
Rulla M. Tamimi
Rulla M. Tamimi Cornell University
Anthony D. Elias
Anthony D. Elias University of Colorado Boulder
Eric P. Winer
Eric P. Winer Yale University
Ian E. Krop
Ian E. Krop Harvard University
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Martin D. McCarter
Martin D. McCarter University of Colorado Anschutz Medical Campus
Lisa A. Carey
Lisa A. Carey University of North Carolina at Chapel Hill
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry can open doors to many exciting and rewarding careers in healthcare and life sciences. As demand grows for specialized roles, online degree pathways make it easier than ever to transition into fast-growing fields. For example, accredited ultrasound tech school online programs allow students to enter medical imaging, while affordable online radiology programs prepare you for essential diagnostic work.

If you are interested in nutritional health and wellness, the best dietitian programs can help you qualify as a registered dietitian, offering services in hospitals, clinics, or through private practice. For those seeking entry into patient care, online medical assisting classes provide comprehensive training with flexible schedules and financial aid options.

Each of these online programs supports diverse interests within biology and healthcare, providing both flexibility and strong job prospects. Whether you plan a clinical, technical, or research-oriented career, online study options help make your professional goals more accessible.

Best Scientists Citing Virginia F. Borges

Trending Scientists

Recently Published Articles